A citation-based method for searching scientific literature

Delin Yuan, Genhong Li, Lian Yu, Yuelong Jiang, Yuanfei Shi, Qiulin Chen, Xiaomei Ma, Lan V Pham, Ken H Young, Manman Deng, Zhihong Fang, Bing Xu. Front Oncol 2021
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
John F Seymour, Thomas J Kipps, Barbara Eichhorst, Peter Hillmen, James D'Rozario, Sarit Assouline, Carolyn Owen, John Gerecitano, Tadeusz Robak, Javier De la Serna,[...]. N Engl J Med 2018
471
100

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Yuankai Shi, Bo Jia, Wei Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang,[...]. J Hematol Oncol 2017
101
50

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Jingsong He, Qingxiao Chen, Huiyao Gu, Jing Chen, Enfan Zhang, Xing Guo, Xi Huang, Haimeng Yan, DongHua He, Yang Yang,[...]. Haematologica 2018
17
50

HDAC Inhibitors in Acute Myeloid Leukemia.
Edurne San José-Enériz, Naroa Gimenez-Camino, Xabier Agirre, Felipe Prosper. Cancers (Basel) 2019
74
50


Cell cycle development.
James A Coffman. Dev Cell 2004
52
50

Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Yin Li, Yan Wang, Yong Zhou, Jie Li, Kai Chen, Leisi Zhang, Manman Deng, Suqi Deng, Peng Li, Bing Xu. Clin Epigenetics 2017
34
50

Histone deacetylase inhibitors and cell death.
Jing Zhang, Qing Zhong. Cell Mol Life Sci 2014
125
50

Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells.
Umamaheswari Natarajan, Thiagarajan Venkatesan, Vijayaraghavan Radhakrishnan, Shila Samuel, Periannan Rasappan, Appu Rathinavelu. Medicina (Kaunas) 2019
16
50

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Sophie Derenne, Brett Monia, Nicholas M Dean, Jennifer K Taylor, Marie-Josée Rapp, Jean-Luc Harousseau, Régis Bataille, Martine Amiot. Blood 2002
351
50

Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Jing Ye, Jie Zha, Yuanfei Shi, Yin Li, Delin Yuan, Qinwei Chen, Fusheng Lin, Zhihong Fang, Yong Yu, Yun Dai,[...]. Clin Epigenetics 2019
25
50

ABT-737 is highly effective against molecular subgroups of multiple myeloma.
Linda Bodet, Patricia Gomez-Bougie, Cyrille Touzeau, Christelle Dousset, Géraldine Descamps, Sophie Maïga, Hervé Avet-Loiseau, Régis Bataille, Philippe Moreau, Steven Le Gouill,[...]. Blood 2011
88
50

HDAC inhibitors: roles of DNA damage and repair.
Carine Robert, Feyruz V Rassool. Adv Cancer Res 2012
90
50

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Steven Le Gouill, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Caroline Bodet-Milin, Sylviane Ragot, Céline Bossard, Nathalie Nadal,[...]. Blood 2021
32
50

p27 and leukemia: cell cycle and beyond.
Anita Roy, Subrata Banerjee. J Cell Physiol 2015
52
50

Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells.
S Inoue, R Walewska, M J S Dyer, G M Cohen. Leukemia 2008
53
50

Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.
Clare M Adams, Scott W Hiebert, Christine M Eischen. Cancer Res 2016
43
50

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Shaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, Thierry Facon, Martine Amiot, Philippe Moreau,[...]. Blood 2017
284
50

Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway.
Liman Lin, Yimei Que, Pingfan Lu, Huimin Li, Min Xiao, Xiaojian Zhu, Dengju Li. Front Pharmacol 2020
9
50

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.
S Wuillème-Toumi, N Robillard, P Gomez, P Moreau, S Le Gouill, H Avet-Loiseau, J-L Harousseau, M Amiot, R Bataille. Leukemia 2005
251
50

PUMA and BIM are required for oncogene inactivation-induced apoptosis.
Gregory R Bean, Yogesh Tengarai Ganesan, Yiyu Dong, Shugaku Takeda, Han Liu, Po M Chan, Yafen Huang, Lewis A Chodosh, Gerard P Zambetti, James J-D Hsieh,[...]. Sci Signal 2013
86
50

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.
C Touzeau, C Dousset, S Le Gouill, D Sampath, J D Leverson, A J Souers, S Maïga, M C Béné, P Moreau, C Pellat-Deceunynck,[...]. Leukemia 2014
196
50

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance.
Isha Kapoor, Juraj Bodo, Brian T Hill, Eric D Hsi, Alexandru Almasan. Cell Death Dis 2020
58
50

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Shaji K Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim,[...]. Lancet Oncol 2020
127
50

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Ruiqi Zhu, Li Li, Bao Nguyen, Jaesung Seo, Min Wu, Tessa Seale, Mark Levis, Amy Duffield, Yu Hu, Donald Small. Signal Transduct Target Ther 2021
14
50

BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
S L Locatelli, L Cleris, G G Stirparo, S Tartari, E Saba, M Pierdominici, W Malorni, A Carbone, A Anichini, C Carlo-Stella. Leukemia 2014
39
50

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Elizabeth A Punnoose, Joel D Leverson, Franklin Peale, Erwin R Boghaert, Lisa D Belmont, Nguyen Tan, Amy Young, Michael Mitten, Ellen Ingalla, Walter C Darbonne,[...]. Mol Cancer Ther 2016
173
50

The DNA damage response: ten years after.
J Wade Harper, Stephen J Elledge. Mol Cell 2007
50


Venetoclax for the treatment of multiple myeloma.
Iuliana Vaxman, M Hasib Sidiqi, Morie Gertz. Expert Rev Hematol 2018
21
50

Targeting Bcl-2 for the treatment of multiple myeloma.
Cyrille Touzeau, Paulo Maciag, Martine Amiot, Philippe Moreau. Leukemia 2018
82
50

Chromatin remodelling at a DNA double-strand break site in Saccharomyces cerevisiae.
Toyoko Tsukuda, Alastair B Fleming, Jac A Nickoloff, Mary Ann Osley. Nature 2005
336
50

ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
Shuhei Matsuoka, Bryan A Ballif, Agata Smogorzewska, E Robert McDonald, Kristen E Hurov, Ji Luo, Corey E Bakalarski, Zhenming Zhao, Nicole Solimini, Yaniv Lerenthal,[...]. Science 2007
50

BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells.
Ali Alhoshani, Fahad O Alatawi, Fawaz E Al-Anazi, Ibraheem M Attafi, Asad Zeidan, Abdelali Agouni, Heba M El Gamal, Licia S Shamoon, Sarah Khalaf, Hesham M Korashy. Onco Targets Ther 2020
14
50

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Joanne Smith, Lye Mun Tho, Naihan Xu, David A Gillespie. Adv Cancer Res 2010
800
50

Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
You Zhou, De-Si Pan, Song Shan, Jing-Zhong Zhu, Kun Zhang, Xu-Peng Yue, Li-Ping Nie, Jun Wan, Xian-Ping Lu, Wei Zhang,[...]. Biomed Pharmacother 2014
48
50

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
Lindsey R Pack, Leighton H Daigh, Mingyu Chung, Tobias Meyer. Nat Commun 2021
18
50

BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program.
Decheng Ren, Ho-Chou Tu, Hyungjin Kim, Gary X Wang, Gregory R Bean, Osamu Takeuchi, John R Jeffers, Gerard P Zambetti, James J-D Hsieh, Emily H-Y Cheng. Science 2010
351
50

Cell cycle control in cancer.
Helen K Matthews, Cosetta Bertoli, Robertus A M de Bruin. Nat Rev Mol Cell Biol 2022
108
50

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
Shuangtao Zhao, Rashmi Kanagal-Shamanna, Lucy Navsaria, Chi Young Ok, Shaojun Zhang, Krystle Nomie, Guangchun Han, Dapeng Hao, Holly A Hill, Changying Jiang,[...]. Am J Hematol 2020
38
50

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
Alejo A Morales, Metin Kurtoglu, Shannon M Matulis, Jiangxia Liu, David Siefker, Delia M Gutman, Jonathan L Kaufman, Kelvin P Lee, Sagar Lonial, Lawrence H Boise. Blood 2011
98
50

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, Courtney D DiNardo, Jan Novak, Kamel Laribi, Inho Kim, Don A Stevens, Walter Fiedler, Maria Pagoni,[...]. Blood 2020
264
50

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Kirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, Anna-Maria Fink, Maneesh Tandon, Mark Dixon, Sandra Robrecht, Simon Warburton, Kathryn Humphrey, Olga Samoylova,[...]. N Engl J Med 2019
401
50

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Courtney D DiNardo, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Andrew H Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux,[...]. N Engl J Med 2020
672
50

The E3 ligase RNF8 regulates KU80 removal and NHEJ repair.
Lin Feng, Junjie Chen. Nat Struct Mol Biol 2012
156
50

Pathways and mechanisms of venetoclax resistance.
Prithviraj Bose, Varsha Gandhi, Marina Konopleva. Leuk Lymphoma 2017
133
50

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Y Shi, M Dong, X Hong, W Zhang, J Feng, J Zhu, L Yu, X Ke, H Huang, Z Shen,[...]. Ann Oncol 2015
189
50

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
717
50

Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Magdalena Klanova, Ladislav Andera, Jan Brazina, Jan Svadlenka, Simona Benesova, Jan Soukup, Dana Prukova, Dana Vejmelkova, Radek Jaksa, Karel Helman,[...]. Clin Cancer Res 2016
59
50

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Ruihua Xu,[...]. J Clin Oncol 2016
595
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.